Free shipping on all orders over $ 500

MK 886

Cat. No. M3728
MK 886 Structure


Size Price Availability Quantity
5mg USD 72  USD80 In stock
10mg USD 126  USD140 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

MK 886 inhibits leukotriene biosynthesis (IC50 = 2.5 nM) in vitro and tumor activity in vivo. Displays PPARα antagonist activity. Orally active in vivo. MK-886, has been described that blocks the synthesis of leukotrienes in intact activated leukocytes, but has little or no effect on enzymes involved in leukotriene synthesis, including 5-lipoxygenase, in cell-free systems. MK 886 is a potent inhibitor of leukotriene biosynthesis both in vitro and in vivo indicating that the compound is suitable for studying the role of leukotrienes in a variety of pathological situations. MK 886 inhibited A23187-induced LTB4 formation by rat peripheral blood and elicited PMN.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 472.08
Formula C27H34ClNO2S
CAS Number 118414-82-7
Purity >98%
Solubility DMSO 90 mg/mL
Ethanol 5 mg/mL
Storage at -20°C

Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886.
Kehrer JP, et al. Biochem J. 2001 Jun 15;356(Pt 3):899-906. PMID: 11389700.

L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.
Gillard J, et al. Can J Physiol Pharmacol. 1989 May;67(5):456-64. PMID: 2548691.

Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.
Dixon RA, et al. Nature. 1990 Jan 18;343(6255):282-4. PMID: 2300173.

5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.
Mancini JA, et al. Mol Pharmacol. 1992 Feb;41(2):267-72. PMID: 1538707.

Related Lipoxygenase Products
FPL 62064

FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and prostaglandin synthetase (cyclooxygenase, COX) with IC50 of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and seminal vesicle prostaglandin synthetase, respectively.


AKBA is an active triterpenoid compound from the extract of Boswellia serrata and Boswellia carteri Birdw, exerts anti-inflammatory therapeutic effects and noncompetitively inhibits 5-lipoxygenase, topoisomerase, and leukocyte elastase.


BHQ is a inhibitor of SERCA ATPase.


GSK2190915 (AM803), a potent FLAP inhibitor, prevents the synthesis of leukotrienes and 5-oxo-ETE, with IC50 of 76 nM for inhibition of LTB4 in human blood, provides treatment for asthma.


Zileuton is an orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB4 synthesis with IC50 values of 0.56, 2.3 and 2.6 μM in dog, rat and human blood respectively.

Abmole Inhibitor Catalog 2017

Keywords: MK 886, L-663536 supplier, Lipoxygenase, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.